Nephros Net Worth
Nephros Net Worth Breakdown | NEPH |
Nephros Net Worth Analysis
Nephros' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Nephros' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Nephros' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Nephros' net worth analysis. One common approach is to calculate Nephros' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Nephros' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Nephros' net worth. This approach calculates the present value of Nephros' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Nephros' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Nephros' net worth. This involves comparing Nephros' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Nephros' net worth relative to its peers.
Enterprise Value |
|
To determine if Nephros is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nephros' net worth research are outlined below:
| Nephros generated a negative expected return over the last 90 days | |
| Nephros may become a speculative penny stock | |
| Nephros has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 14.24 M. Net Loss for the year was (1.57 M) with profit before overhead, payroll, taxes, and interest of 4.73 M. | |
| Nephros has a poor financial position based on the latest SEC disclosures | |
| About 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from insidermonkey.com: Nephros, Inc. Q3 2024 Earnings Call Transcript |
Nephros Quarterly Good Will |
|
Nephros uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nephros. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nephros' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Nephros' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nephros is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nephros backward and forwards among themselves. Nephros' institutional investor refers to the entity that pools money to purchase Nephros' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 14.9 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 13.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 10.8 K | Tower Research Capital Llc | 2024-06-30 | 3.7 K | Jpmorgan Chase & Co | 2024-06-30 | 222 | Bank Of America Corp | 2024-06-30 | 76.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Granite Investment Partners, Llc | 2024-09-30 | 0.0 | Goss Wealth Management Llc | 2024-06-30 | 0.0 | Wexford Capital Lp | 2024-06-30 | 3.6 M | Vanguard Group Inc | 2024-09-30 | 202 K |
Follow Nephros' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.34 M.Market Cap |
|
Project Nephros' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.19) | (0.20) |
When accessing Nephros' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Nephros' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nephros' profitability and make more informed investment decisions.
Evaluate Nephros' management efficiency
Nephros has return on total asset (ROA) of (0.0796) % which means that it has lost $0.0796 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1561) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Nephros' Asset Turnover is increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.80 | 0.84 | |
| Tangible Book Value Per Share | 0.67 | 0.70 | |
| Enterprise Value Over EBITDA | (24.27) | (23.05) | |
| Price Book Value Ratio | 4.30 | 3.48 | |
| Enterprise Value Multiple | (24.27) | (23.05) | |
| Price Fair Value | 4.30 | 3.48 | |
| Enterprise Value | 33.5 M | 18.9 M |
Effective leadership at Nephros drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 1.1353 | Revenue 13.8 M | Quarterly Revenue Growth (0.08) | Revenue Per Share 1.313 | Return On Equity (0.16) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nephros insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nephros time-series forecasting models is one of many Nephros' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nephros' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Nephros Earnings per Share Projection vs Actual
Nephros Corporate Management
| Vashone Thomas | Regulatory, Quality | Profile | |
| Joleen Turner | VP Devel | Profile | |
| Judy CFA | Chief Officer | Profile | |
| Judy Mazzini | Controller | Profile | |
| MS MBA | Inc Products | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share 1.313 | Quarterly Revenue Growth (0.08) | Return On Assets (0.08) | Return On Equity (0.16) |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.